News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Galimedix Therapeutics to present promising pre-clinical data with next generation oral amyloid beta aggregation modulator at AD/PD™ 2026 Conference
Galimedix Therapeutics to present pre-clinical data on new oral amyloid beta modulator at AD/PD™ 2026 Conference, discussing GAL-201 prodrugs and improved pharmacokinetics -
-
-
COMMUNIQUÉ DE PRESSE
Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Galimedix Therapeutics presents compelling Phase 1 study results at CTAD 2025, demonstrating excellent safety and pharmacokinetics of GAL-101, planning Phase 2 study in Alzheimer's disease -
